688336 三生国健
交易中 04-16 11:21:59
资讯
新帖
简况
4月9日三生国健跌5.27%,广发医疗保健股票A基金重仓该股
证券之星 · 04-09
4月9日三生国健跌5.27%,广发医疗保健股票A基金重仓该股
韧性十足!制药板块逆市飘红,场内唯一药ETF(562050)收复半年线!三生国健业绩炸裂,股价狂飙14%创新高
新浪基金 · 04-02
韧性十足!制药板块逆市飘红,场内唯一药ETF(562050)收复半年线!三生国健业绩炸裂,股价狂飙14%创新高
国金证券:给予三生国健买入评级
证券之星 · 04-02
国金证券:给予三生国健买入评级
三生国健发布2025年业绩,营收同比增长252.63%
蓝鲸财经 · 04-01
三生国健发布2025年业绩,营收同比增长252.63%
图解三生国健年报:第四季度单季净利润同比增长430.28%
证券之星 · 03-31
图解三生国健年报:第四季度单季净利润同比增长430.28%
3月30日三生国健涨13.87%,广发医疗保健股票A基金重仓该股
证券之星 · 03-30
3月30日三生国健涨13.87%,广发医疗保健股票A基金重仓该股
3月23日三生国健跌6.38%,广发医疗保健股票A基金重仓该股
证券之星 · 03-23
3月23日三生国健跌6.38%,广发医疗保健股票A基金重仓该股
医药板块震荡走强 三生国健涨超8%
人民财讯 · 03-17
医药板块震荡走强 三生国健涨超8%
每周股票复盘:三生国健(688336)2025年净利增317.09%
证券之星 · 03-01
每周股票复盘:三生国健(688336)2025年净利增317.09%
2月27日三生国健发布公告,股东减持589.48万股
证券之星 · 02-27
2月27日三生国健发布公告,股东减持589.48万股
三生国健(688336.SH):重组抗IL-4Rα人源化单克隆抗体注射液新药上市申请获受理
智通财经 · 02-25
三生国健(688336.SH):重组抗IL-4Rα人源化单克隆抗体注射液新药上市申请获受理
三生国健(688336)披露2025年年度业绩快报公告,2月24日股价下跌0.53%
证券之星 · 02-24
三生国健(688336)披露2025年年度业绩快报公告,2月24日股价下跌0.53%
与辉瑞达成重要合作,三生国健2025年净利润同比增长317.09%
财闻 · 02-24
与辉瑞达成重要合作,三生国健2025年净利润同比增长317.09%
三生国健(688336.SH)2025年度归母净利润29.39亿元 同比增长317.09%
智通财经 · 02-24
三生国健(688336.SH)2025年度归母净利润29.39亿元 同比增长317.09%
【读财报】医药生物行业2025年业绩预告透视:五成公司预喜 药明康德、三生国健等10家公司预盈超10亿元
新华财经 · 02-24
【读财报】医药生物行业2025年业绩预告透视:五成公司预喜 药明康德、三生国健等10家公司预盈超10亿元
每周股票复盘:三生国健(688336)安沐奇塔单抗获批上市
证券之星 · 02-15
每周股票复盘:三生国健(688336)安沐奇塔单抗获批上市
每周股票复盘:三生国健(688336)预计2025年净利29亿元
证券之星 · 02-01
每周股票复盘:三生国健(688336)预计2025年净利29亿元
1月27日三生国健涨10.93%,广发医疗保健股票A基金重仓该股
证券之星 · 01-27
1月27日三生国健涨10.93%,广发医疗保健股票A基金重仓该股
三生国健涨10.93%,开源证券二个月前给出“买入”评级
证券之星 · 01-27
三生国健涨10.93%,开源证券二个月前给出“买入”评级
三生国健(688336)披露2025年年度业绩预告,1月26日股价下跌2.54%
证券之星 · 01-26
三生国健(688336)披露2025年年度业绩预告,1月26日股价下跌2.54%
加载更多
公司概况
公司名称:
三生国健药业(上海)股份有限公司
所属行业:
医药制造业
上市日期:
2020-07-22
主营业务:
三生国健药业(上海)股份有限公司的主营业务是抗体药物的研发、生产和销售。公司的主要产品是益赛普、赛普汀、健尼哌、益赛拓。公司是“免疫与炎症全国重点实验室”依托单位、拥有抗体药物国家工程研究中心、国家企业技术中心、上海市抗体技术创新中心、上海抗体工程技术研究中心等国家级和上海市级高新技术平台,承担过国家重大新药创制、“863”计划、国家发改委及上海市重大项目及各部委课题百余项,多次获得上海市级和浦东新区科学技术奖。
发行价格:
28.18
{"stockData":{"symbol":"688336","market":"SH","secType":"STK","nameCN":"三生国健","latestPrice":86.32,"timestamp":1776309719000,"preClose":89.28,"halted":0,"volume":8441177,"delay":0,"changeRate":-0.0332,"floatShares":617000000,"shares":618000000,"eps":8.2417,"marketStatus":"交易中","change":-2.96,"latestTime":"04-16 11:21:59","open":86.65,"high":88.18,"low":83.53,"amount":726000000,"amplitude":0.0521,"askPrice":86.4,"askSize":43,"bidPrice":86.33,"bidSize":10,"shortable":0,"etf":0,"ttmEps":8.2417,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1776310200000},"marketStatusCode":2,"adr":0,"adjPreClose":89.28,"symbolType":"stock_kcb","openAndCloseTimeList":[[1776303000000,1776310200000],[1776315600000,1776322800000]],"highLimit":98.21,"lowLimit":80.35,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":618086503,"isCdr":false,"pbRate":6.53,"roa":"--","peRate":10.473567,"roe":"41.32%","epsLYR":4.7,"committee":-0.196078,"marketValue":53353000000,"turnoverRate":0.0137,"status":1,"floatMarketCap":53241000000},"requestUrl":"/m/hq/s/688336","defaultTab":"news","newsList":[{"id":"2626590262","title":"4月9日三生国健跌5.27%,广发医疗保健股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2626590262","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626590262?lang=zh_cn&edition=full","pubTime":"2026-04-09 16:21","pubTimestamp":1775722864,"startTime":"0","endTime":"0","summary":"证券之星消息,4月9日三生国健跌5.27%,收盘报82.1元,换手率2.35%,成交量14.48万手,成交额11.98亿元。根据2025基金年报公募基金重仓股数据,重仓该股的公募基金共22家,其中持有数量最多的公募基金为广发基金的广发医疗保健股票A。广发医疗保健股票A目前规模为40.74亿元,最新净值1.9286,较上一交易日上涨0.75%,近一年上涨14.0%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040900025332.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688336"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624573327","title":"韧性十足!制药板块逆市飘红,场内唯一药ETF(562050)收复半年线!三生国健业绩炸裂,股价狂飙14%创新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2624573327","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624573327?lang=zh_cn&edition=full","pubTime":"2026-04-02 14:31","pubTimestamp":1775111460,"startTime":"0","endTime":"0","summary":"4月2日午后,A股加速走低,沪指跌逾1%。全市场唯一表征制药板块整体表现的药ETF华宝盘中一度涨超1%,逆市收复半年线! 成份股方面,创新药龙头三生国健绩后狂飙逾14%创历史新高! 整体统计,药ETF华宝已披露2025年全年业绩28家成份股公司中,23家实现盈利,16家净利同比正增长,三生国健、荣昌生物净利增速暂居前二位,分别高达311%、148%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-04-02/doc-inhtaviy1072263.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01477","562050","BK0239","BK1574","688336","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624522314","title":"国金证券:给予三生国健买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2624522314","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624522314?lang=zh_cn&edition=full","pubTime":"2026-04-02 11:54","pubTimestamp":1775102046,"startTime":"0","endTime":"0","summary":"国金证券股份有限公司甘坛焕,唐玉青近期对三生国健进行研究并发布了研究报告《授权收入推动业绩增长,26年管线密集兑现》,给予三生国健买入评级。 风险提示 研发及商业化不及预期风险、大股东持股集中及关联交易风险最新盈利预测明细如下:该股最近90天内共有2家机构给出评级,买入评级1家,增持评级1家;过去90天内机构目标均价为72.96。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040200016376.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624592452","title":"三生国健发布2025年业绩,营收同比增长252.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624592452","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624592452?lang=zh_cn&edition=full","pubTime":"2026-04-01 18:35","pubTimestamp":1775039721,"startTime":"0","endTime":"0","summary":"公司2025年实现营业收入达42.00亿元,同比增长252.63%;归母净利润29.0亿元,同比增幅311.5%;扣非净利润为27.7亿元,同比增长高达1025.0%。2025年毛利率达92.07%,同比提升1.92个百分点;净利率为68.87%,同比大幅提升34.44个百分点。在营收扩张背景下,销售费用同比下降16.33%至1.99亿元,进一步强化了净利率提升效应。研发费用为4.35亿元,同比增长22.00%,占营收比重为10.36%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1775034411736558259","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["688336"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623323046","title":"图解三生国健年报:第四季度单季净利润同比增长430.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623323046","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623323046?lang=zh_cn&edition=full","pubTime":"2026-03-31 02:37","pubTimestamp":1774895866,"startTime":"0","endTime":"0","summary":"证券之星消息,三生国健2025年年报显示,当年度公司主营收入41.99亿元,同比上升251.81%;归母净利润28.99亿元,同比上升311.49%;扣非净利润27.66亿元,同比上升1024.98%;其中2025年第四季度,公司单季度主营收入30.83亿元,同比上升1113.05%;单季度归母净利润25.0亿元,同比上升430.28%;单季度扣非净利润24.14亿元,同比上升8243.6%;负债率6.06%,投资收益7636.32万元,财务费用-4267.45万元,毛利率92.07%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026033100005950.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623977323","title":"3月30日三生国健涨13.87%,广发医疗保健股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2623977323","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623977323?lang=zh_cn&edition=full","pubTime":"2026-03-30 16:26","pubTimestamp":1774859181,"startTime":"0","endTime":"0","summary":"证券之星消息,3月30日三生国健涨13.87%创60日新高,收盘报81.45元,换手率2.17%,成交量13.39万手,成交额10.61亿元。根据2025基金年报公募基金重仓股数据,重仓该股的公募基金共22家,其中持有数量最多的公募基金为广发基金的广发医疗保健股票A。广发医疗保健股票A目前规模为40.74亿元,最新净值1.8152,较上一交易日上涨5.12%,近一年上涨4.63%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026033000021500.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688336"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621768027","title":"3月23日三生国健跌6.38%,广发医疗保健股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2621768027","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621768027?lang=zh_cn&edition=full","pubTime":"2026-03-23 16:38","pubTimestamp":1774255110,"startTime":"0","endTime":"0","summary":"证券之星消息,3月23日三生国健跌6.38%,收盘报65.56元,换手率1.61%,成交量9.91万手,成交额6.66亿元。根据2025基金年报公募基金重仓股数据,重仓该股的公募基金共22家,其中持有数量最多的公募基金为广发基金的广发医疗保健股票A。广发医疗保健股票A目前规模为40.74亿元,最新净值1.7458,较上一交易日下跌1.22%,近一年上涨1.51%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032300025329.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688336"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620541482","title":"医药板块震荡走强 三生国健涨超8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620541482","media":"人民财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620541482?lang=zh_cn&edition=full","pubTime":"2026-03-17 10:36","pubTimestamp":1773714990,"startTime":"0","endTime":"0","summary":"人民财讯3月17日电,医药板块震荡走强,三生国健涨超8%,苑东生物、荣昌生物、海思科、泽璟制药、君实生物等涨幅居前。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603173674269731.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK1161","159938","09939","688336","BK1515","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616784356","title":"每周股票复盘:三生国健(688336)2025年净利增317.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616784356","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616784356?lang=zh_cn&edition=full","pubTime":"2026-03-01 01:58","pubTimestamp":1772301489,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘,三生国健报收于59.38元,较上周的58.8元上涨0.99%。本周关注点来自业绩披露要点:三生国健2025年归母净利润同比增长317.09%。其一致行动人合计持股比例由84.96%减少至83.83%。三生国健股东达佳国际(香港)有限公司于2025年12月19日至2026年2月27日期间减持公司股份5,894,823股,占总股本0.95%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000540.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614586128","title":"2月27日三生国健发布公告,股东减持589.48万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2614586128","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614586128?lang=zh_cn&edition=full","pubTime":"2026-02-27 20:02","pubTimestamp":1772193722,"startTime":"0","endTime":"0","summary":"证券之星消息,2月27日三生国健发布公告《三生国健:股东权益变动触及1%刻度暨减持股份结果公告》,其股东达佳国际(香港)有限公司于2025年12月19日至2026年2月27日间合计减持589.48万股,占公司目前总股本的0.9537%,变动期间该股股价上涨0.8%,截止2月27日收盘报59.38元。股东增减持详情见下表:根据三生国健2025年三季报公布的十大股东详情如下:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700037243.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614087237","title":"三生国健(688336.SH):重组抗IL-4Rα人源化单克隆抗体注射液新药上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2614087237","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614087237?lang=zh_cn&edition=full","pubTime":"2026-02-25 21:24","pubTimestamp":1772025865,"startTime":"0","endTime":"0","summary":"智通财经APP讯,三生国健(688336.SH)公告,公司收到国家药品监督管理局核准签发的《受理通知书》,公司产品重组抗IL-4Rα人源化单克隆抗体注射液(研发代码:SSGJ-611)的新药上市申请(NDA)获得受理。公告显示,SSGJ-611是公司自主研发设计、筛选并人源化的抗IL-4Rα单克隆抗体,具有全新的氨基酸序列。SSGJ-611能够通过特异性的结合IL-4Rα,阻断IL-4和IL-13的信号传导达到缓解特应性皮炎等疾病的作用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1407304.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688336"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613678797","title":"三生国健(688336)披露2025年年度业绩快报公告,2月24日股价下跌0.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613678797","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613678797?lang=zh_cn&edition=full","pubTime":"2026-02-24 18:30","pubTimestamp":1771929040,"startTime":"0","endTime":"0","summary":"截至2026年2月24日收盘,三生国健报收于58.49元,较前一交易日下跌0.53%,最新总市值为361.52亿元。该股当日开盘59.59元,最高59.61元,最低58.0元,成交额达1.83亿元,换手率为0.5%。近日,三生国健药业(上海)股份有限公司发布2025年年度业绩快报,报告期内实现营业总收入419,911.84万元,同比增长251.81%;归属于母公司所有者的净利润为293,871.44万元,同比增长317.09%;扣除非经常性损益后的净利润为280,533.07万元,同比增长1,041.01%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400037464.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613926347","title":"与辉瑞达成重要合作,三生国健2025年净利润同比增长317.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613926347","media":"财闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613926347?lang=zh_cn&edition=full","pubTime":"2026-02-24 16:24","pubTimestamp":1771921452,"startTime":"0","endTime":"0","summary":"2月24日,三生国健披露2025年年度业绩快报,2025年全年营业收入41.99亿元,同比增长251.81%;归属于上市公司股东的净利润29.39亿元,同比增长317.09%;基本每股收益4.76元,上年同期1.14元,同比增长317.54%。公司表示,本期业绩变化主要由于报告期内公司与辉瑞达成重要合作,公司收到辉瑞公司就707项目支付的授权许可首付款并相应确认收入约28.9亿元。于本次交易中所约定的销售里程碑款项和特许权使用费的支付,须以约定的销售达成情况作为触发条件。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224162726a71914b3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224162726a71914b3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BLSP4239.USD","BK4592","IE000M9KFDE8.USD","688336","LU0225284248.USD","LU1894683264.USD","BK4599","LU0456855351.SGD","LU1023059063.AUD","SG9999013999.USD","BK4550","BK4007","SG9999002232.USD","LU1066053197.SGD","SG9999001176.USD","LU0985481810.HKD","LU0289739699.SGD","LU0306806265.USD","BK4581","SG9999011175.SGD","BK4533","LU1057294990.SGD","BK4568","SG9999002224.SGD","BK4534","LU0225771236.USD","SGXZ57979304.SGD","IE00BLSP4452.SGD","LU0321505439.SGD","IE00B19Z3581.USD","BK4585","LU0170899867.USD","LU0122379950.USD","LU0868494617.USD","LU1883839398.USD","IE00BBT3K403.USD","LU0058720904.USD","SG9999001176.SGD","LU1894683348.USD","IE00B19Z3B42.SGD","SG9999003800.SGD","LU0321505868.SGD","LU0234572021.USD","LU1066051498.USD","IE0002270589.USD","LU0306807586.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613270793","title":"三生国健(688336.SH)2025年度归母净利润29.39亿元 同比增长317.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613270793","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613270793?lang=zh_cn&edition=full","pubTime":"2026-02-24 16:20","pubTimestamp":1771921212,"startTime":"0","endTime":"0","summary":"智通财经APP讯,三生国健(688336.SH)发布公告,2025年公司实现营业收入41.99亿元,较上年增加251.81%。归属于母公司所有者的净利润29.39亿元,较上年涨幅317.09%。营业总收入、营业利润、利润总额、归属于母公司所有者的净利润、归属于母公司所有者的扣除非经常性损益的净利润、基本每股收益、总资产、归属于母公司的所有者权益以及归属于母公司所有者的每股净资产相比上年同期均出现较大幅度的增长,该增长主要由于报告期内公司与辉瑞公司(PfizerInc.)达成重要合作,公司收到辉瑞公司就707项目支付的授权许可首付款并相应确认收入约28.90亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406652.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"三生国健(688336.SH)2025年度归母净利润29.39亿元 同比增长317.09%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688336"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613755774","title":"【读财报】医药生物行业2025年业绩预告透视:五成公司预喜 药明康德、三生国健等10家公司预盈超10亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2613755774","media":"新华财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613755774?lang=zh_cn&edition=full","pubTime":"2026-02-24 07:20","pubTimestamp":1771888844,"startTime":"0","endTime":"0","summary":"新华财经北京2月24日电截至2026年2月12日,根据申万行业分类,A股医药生物行业逾500家上市公司,其中约274家已披露2025年业绩预告。整体来看,已披露2025年业绩预告的274家医药生物上市公司中,业绩偏正面(包括预增、略增、扭亏及续盈)的企业合计90家。137家医药生物上市公司2025年实现盈利,占比50%,其中10家归母净利润超10亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602243652109539.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["163118","000808.SH","688336","603259","02359"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611143999","title":"每周股票复盘:三生国健(688336)安沐奇塔单抗获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2611143999","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611143999?lang=zh_cn&edition=full","pubTime":"2026-02-15 01:29","pubTimestamp":1771090149,"startTime":"0","endTime":"0","summary":"截至2026年2月13日收盘,三生国健报收于58.8元,较上周的60.42元下跌2.68%。本周,三生国健2月10日盘中最高价报61.47元。2月13日盘中最低价报58.58元。三生国健当前最新总市值363.43亿元,在生物制品板块市值排名6/51,在两市A股市值排名573/5189。目前该药另有两项适应症处于III期临床阶段。此次获批有助于丰富公司自免产品管线,提升市场竞争力,但对未来销售情况存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021500000276.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608077487","title":"每周股票复盘:三生国健(688336)预计2025年净利29亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608077487","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608077487?lang=zh_cn&edition=full","pubTime":"2026-02-01 03:07","pubTimestamp":1769886430,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘,三生国健报收于60.22元,较上周的58.76元上涨2.48%。本周,三生国健1月27日盘中最高价报66.28元。公司公告汇总:因收到707项目授权许可首付款,确认收入约28.90亿元人民币。三生国健发布业绩预告,预计2025年全年归属净利润盈利约29亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100000994.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606436201","title":"1月27日三生国健涨10.93%,广发医疗保健股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2606436201","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606436201?lang=zh_cn&edition=full","pubTime":"2026-01-27 16:35","pubTimestamp":1769502927,"startTime":"0","endTime":"0","summary":"证券之星消息,1月27日三生国健涨10.93%,收盘报63.53元,换手率3.27%,成交量20.14万手,成交额12.7亿元。根据2025基金年报公募基金重仓股数据,重仓该股的公募基金共22家,其中持有数量最多的公募基金为广发基金的广发医疗保健股票A。广发医疗保健股票A目前规模为40.74亿元,最新净值1.8427,较上一交易日下跌0.6%,近一年上涨16.15%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700027009.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688336"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606201428","title":"三生国健涨10.93%,开源证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2606201428","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606201428?lang=zh_cn&edition=full","pubTime":"2026-01-27 16:35","pubTimestamp":1769502921,"startTime":"0","endTime":"0","summary":"今日三生国健涨10.93%,收盘报63.53元。2025年10月28日,开源证券研究员余汝意,余克清,汪晋发布了对三生国健的研报《公司信息更新报告:业绩同环比增速稳健,在研项目稳步推进》,该研报对三生国健给出“买入”评级。研报中预计2025-2027年归母净利润为4.64/5.43/6.81亿元,EPS为0.75/0.88/1.1元,当前股价对应PE为79.7/68.1/54.4倍,考虑公司自免新产品即将上市,维持“买入”评级。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为59.94%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700027002.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606998249","title":"三生国健(688336)披露2025年年度业绩预告,1月26日股价下跌2.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606998249","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606998249?lang=zh_cn&edition=full","pubTime":"2026-01-26 22:49","pubTimestamp":1769438946,"startTime":"0","endTime":"0","summary":"截至2026年1月26日收盘,三生国健报收于57.27元,较前一交易日下跌2.54%,最新总市值为353.98亿元。该股当日开盘58.62元,最高58.98元,最低56.88元,成交额达1.92亿元,换手率为0.54%。近日,三生国健药业(上海)股份有限公司发布2025年年度业绩预告。本次业绩预告未经注册会计师审计,最终数据以正式披露的2025年年报为准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600036761.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688336"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1776309724213,"stockEarnings":[{"period":"1week","weight":0.0301},{"period":"1month","weight":0.5285},{"period":"3month","weight":0.5551},{"period":"6month","weight":0.5117},{"period":"1year","weight":2.1378},{"period":"ytd","weight":0.4987}],"compareEarnings":[{"period":"1week","weight":0.0081},{"period":"1month","weight":-0.0141},{"period":"3month","weight":-0.0208},{"period":"6month","weight":0.0488},{"period":"1year","weight":0.2324},{"period":"ytd","weight":0.0147}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"三生国健药业(上海)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"15813人(较上一季度增加31.98%)","perCapita":"39004股","listingDate":"2020-07-22","address":"上海市浦东新区中国(上海)自由贸易试验区李冰路399号","registeredCapital":"61808万元","survey":" 三生国健药业(上海)股份有限公司的主营业务是抗体药物的研发、生产和销售。公司的主要产品是益赛普、赛普汀、健尼哌、益赛拓。公司是“免疫与炎症全国重点实验室”依托单位、拥有抗体药物国家工程研究中心、国家企业技术中心、上海市抗体技术创新中心、上海抗体工程技术研究中心等国家级和上海市级高新技术平台,承担过国家重大新药创制、“863”计划、国家发改委及上海市重大项目及各部委课题百余项,多次获得上海市级和浦东新区科学技术奖。","listedPrice":28.18},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.41.0","shortVersion":"4.41.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"三生国健(688336)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供三生国健(688336)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"三生国健,688336,三生国健股票,三生国健股票老虎,三生国健股票老虎国际,三生国健行情,三生国健股票行情,三生国健股价,三生国健股市,三生国健股票价格,三生国健股票交易,三生国健股票购买,三生国健股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"三生国健(688336)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供三生国健(688336)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}